HRP20181566T1 - Biomarkeri raka i njihove uporabe - Google Patents

Biomarkeri raka i njihove uporabe

Info

Publication number
HRP20181566T1
HRP20181566T1 HRP20181566TT HRP20181566T HRP20181566T1 HR P20181566 T1 HRP20181566 T1 HR P20181566T1 HR P20181566T T HRP20181566T T HR P20181566TT HR P20181566 T HRP20181566 T HR P20181566T HR P20181566 T1 HRP20181566 T1 HR P20181566T1
Authority
HR
Croatia
Prior art keywords
cancer biomarkers
biomarkers
cancer
Prior art date
Application number
HRP20181566TT
Other languages
English (en)
Croatian (hr)
Inventor
Kinmei LEUNG
Haijun Sun
Sarah Batey
Robert Rowland
Original Assignee
F-Star Biotechnology Ltd.
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F-Star Biotechnology Ltd., F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. filed Critical F-Star Biotechnology Ltd.
Publication of HRP20181566T1 publication Critical patent/HRP20181566T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20181566TT 2013-10-04 2014-10-03 Biomarkeri raka i njihove uporabe HRP20181566T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof
PCT/GB2014/052994 WO2015049537A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
EP14781645.8A EP3052647B1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
HRP20181566T1 true HRP20181566T1 (hr) 2018-11-30

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181566TT HRP20181566T1 (hr) 2013-10-04 2014-10-03 Biomarkeri raka i njihove uporabe

Country Status (20)

Country Link
US (1) US20160289336A1 (https=)
EP (1) EP3052647B1 (https=)
JP (1) JP6449308B2 (https=)
KR (1) KR20160092992A (https=)
CN (1) CN105722997A (https=)
AU (1) AU2014330942A1 (https=)
BR (1) BR112016007348A2 (https=)
CA (1) CA2925186A1 (https=)
CL (1) CL2016000777A1 (https=)
DK (1) DK3052647T3 (https=)
EA (1) EA201690450A1 (https=)
ES (1) ES2687783T3 (https=)
GB (1) GB201317622D0 (https=)
HR (1) HRP20181566T1 (https=)
IL (1) IL244510A0 (https=)
LT (1) LT3052647T (https=)
MX (1) MX2016004286A (https=)
PE (1) PE20160950A1 (https=)
SG (1) SG11201602605TA (https=)
WO (1) WO2015049537A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP3241842B1 (en) 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201642897A (zh) * 2015-04-08 2016-12-16 F 星生物科技有限公司 Her2結合劑治療
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR20190022632A (ko) 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
KR20210028155A (ko) * 2018-05-17 2021-03-11 이뮤놈 인코포레이티드 Ch3 도메인 에피토프 태그
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
BR112021000282A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a cd137 e ox40
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103555733A (zh) * 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
EP3241842B1 (en) * 2007-06-26 2024-01-31 F-star Therapeutics Limited Display of binding agents
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
EP2435071A1 (en) * 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
PE20160950A1 (es) 2016-10-02
EA201690450A1 (ru) 2016-10-31
HK1221746A1 (en) 2017-06-09
JP2016533395A (ja) 2016-10-27
AU2014330942A1 (en) 2016-05-19
CL2016000777A1 (es) 2017-02-17
EP3052647B1 (en) 2018-07-11
BR112016007348A2 (pt) 2018-01-23
ES2687783T3 (es) 2018-10-29
EP3052647A1 (en) 2016-08-10
US20160289336A1 (en) 2016-10-06
CN105722997A (zh) 2016-06-29
IL244510A0 (en) 2016-04-21
LT3052647T (lt) 2018-10-25
JP6449308B2 (ja) 2019-01-09
MX2016004286A (es) 2017-01-18
CA2925186A1 (en) 2015-04-09
WO2015049537A1 (en) 2015-04-09
SG11201602605TA (en) 2016-04-28
KR20160092992A (ko) 2016-08-05
GB201317622D0 (en) 2013-11-20
DK3052647T3 (en) 2018-10-22

Similar Documents

Publication Publication Date Title
NL301171I1 (nl) Tigolaner
NO2023037I1 (no) Mirikizumab
HRP20181566T1 (hr) Biomarkeri raka i njihove uporabe
NO2021038I1 (no) lumasiran
DK3043784T3 (da) Arylethere og anvendelser deraf
EP2957784A4 (en) SLIDING ELEMENT
HUE037097T2 (hu) Hõszigetelõpanel
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK2956698T3 (da) Bindestrimler
EP3014631A4 (en) METALLIC NANOMESH
DK2946640T3 (da) Langmuir-probe
IL240499A0 (en) Caix stratification based cancer treatment
DE102013106534B8 (de) Chromatographiepipettenspitze
NL301170I1 (nl) Somatrogon
PT3013706T (pt) Difusor
IL244632A0 (en) Cancer biomarker and diagnostic
DK2988732T3 (da) Modificerede hydrogeler
DE112014001252A5 (de) Aufbissschiene
EP3085782A4 (en) 2-DESOXYSCYLLOINOSOSE REDUCTASE
FI10343U1 (fi) Mittateippi
CO6790166U1 (es) Cuadernos multiaccesorios
ES1085954Y (es) Cuadernillo para escolares
DE112014005422A5 (de) Friktionsfalschdrallaggregat
UY4316S (es) Diseño celosías
BR302013004984S1 (pt) Configuração aplicada em tamanco